Tevogen Bio Holdings Inc. · NASDAQ:TVGN
Tevogen Bio — Semper Paratus Acquisition — SPAC Merger (November 2023)
37 slides from Tevogen Bio's SPAC merger presentation, Nov 17, 2023
Slide 1: Tevogen Bio Corporate Overview
© TEVOGEN BIO” Oncology | Neurology | Virology A healthier world is possible when lifesaving innovations are within the reach of all oe ome ‘CORPORATE OVERVIEW. ' 4 « —
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forwaré-lookng statements, including without limitation statements relating to the business combination {the “Transaction’) between Tevogen Bio nc ("Tevogen") and Semper Paratus ‘Acquistion Corporation ("Semper Paratus"), including the an
Slide 3: About Semper Paratus Acquisition Corporation
About Semper Paratus Acquisition Corporation Semper Paratus Acquisition Corporation Management Team Focus Semper Paratus Acquisition Corporation (Nasdaq: LGST) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purc
Slide 4: Transaction Overview
Transaction Overview Key Transaction Highlights Illustrative Sources & Uses + Semper Paratus Acquisition Corporation (LGST) has agreed + Advance TVGN 489 through completion of a potentially pivotal to purchase Tevogen Bio Inc. (“Tevogen”) at an enterprise clinical trial in acute COVID-19 patients wi
Slide 5: It's the insight behind the investment, not its magnitude
It's the insight behind the investment, not its magnitude, that will pave the way for a healthier tomorrow Health Care System Performance Compared to Spending { Bloomberg gow US Health Spending Edges Past $4.3 Trillion as Covid nor 14,2022 at 400 PM EST HOW MUCH DOES THE UNITED STATES SPEND ON LTHCA
Slide 6: Founded with a Purpose | Our Mission
Founded with a Purpose | Our Mission Affordability To be the very first biotechnology company offering commercially attractive, economically viable, and cost-effective personalized T cell therapies for large populations. Acce: ity To leverage our advanced science and innovative business models to ov
Slide 7: Our Vision Lies Beyond Leading Biopharma
Our Vision Lies Beyond Leading Biopharma In our first chapter, Tevogen Bio has developed quickly from concept to innovative clinical-stage biotech company, with a successful proof-of-concept trial of the first clinical product from its next generation T cell therapy platform, robust intellectual pro
Slide 8: Clinical-Stage Specialty Immunotherapy Company
Clinical-Stage Specialty Immunotherapy Company We are a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes (“CD8+ CTLs” or “CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infec
Slide 9: Agility of a Startup, Experience of a Corporation
Agility of a Startup, Experience of a Corporation May 2021 Dec ‘21 - Jan ‘22 Feb - May 2022 Jan 2023 Nov 2023 @ Ambulatory acute-risk. COVID-19 treatment IND cleared by FDA (Tv_n 489) June 2020 Tevogen Founded @ 3 granted US patents (now: also 7 pending, 5 exUS patent applications) @ Established cor
Slide 10: Tevogen Bio to become publicly listed via business combination with Semper Paratus
Tevogen Bio to become publicly listed via business combination with Semper Paratus Acquisition Corporation, at an expected enterprise value of $1.2 billion — June 28, 2023 —— ANNUAL DINNER MEET INNOVATION cELEBRA
Slide 11: Leadership with diversified experience across healthcare
"When affordability of lifesaving medications is paired with a profitable business model, society prospers" - Tevogen Leadership, June 2020 fe ee ey Ryan Sadi, MD, Nel Fomenbers, Sadiq Khan, MBA Kirti Desai, PA Stephen Chen, Mittul Mehta Dolores Grosso, Judy Akhtar, pH Chief Commercial Chief Financ
Slide 12: Board of Directors & Corporate Advisory Board
2 Board of Directors & Corporate Advisory Board " Ryan Saadi, MD, MPH Curtis Patton, PhD ‘Susan Podlogar, MBA Lindee Goh, PhD Jeffrey Feike, MPH Chair, Board of Directors Board of Directors Board of Directors Board of Directors Board of Dicectors (EO, Tevogen Bo fessor Emeritus of (Chief HR Officer,
Slide 13: Tevogen's T Cell Therapy Platform - ExacTcell
Tevogen's T Cell Therapy Platform - ExacTcell™ Designed to overcome key hurdles to unlock the full potential of T Cell Therapies lection and expansion of naturally occurring, genetically unmodified CD8+ CTLs to target multiple, distinct, cd antigens present ‘only’ on virus-infected or malignant cell
Slide 14: Uniqueness of ExacTcell Platform vs CAR-T
Autologous CAR-T Platform ‘Target antigens present on both healthy and diseased cells Genetically modified T cells High incidence of Serious Adverse Events ("SAEs"), including Cytokine Release Syndrome ("CRS"), neurological toxicities, and others Need for specialized medical facilities |3.t0-6-week
Slide 15: CD8+ CTLs Identify and Kill Infected or Malignant Cells
CD8+ CTLs Identify and Kill Infected or Malignant Cells Through the Recognition of Antigenic Peptides on Their Surfaces a T Cell Receptor Peptide HLA Class-1 CD8+ T cell Infected/malignant cell =» Most CTLs, including those developed with ExacTcell, express T cell receptors (“TCRs”), which are surfa
Slide 16: Potentially the First Personalized Immunotherapy for Large Patient Populations
Potentially the First Personalized Immunotherapy for Large Patient Populations o T lymphocytes CD8+ cell education Target specific Cytotoxic CD8+ Rapid HLA matched from donor to recognize multiple cytotoxic CD8+ lymphocytes expanded to therapeutic infused in proactively selected lymphocyte yield hun
Slide 17: Product Development Prioritization: Prevalence, Unmet Need & Access Landscape
Product Development Prioritization: Prevalence, Unmet Need & Access Landscape @ High-risk COVID-19 patients @ Immune compromised and elderly © Therapeutic options available COVID-19 Long COVID a @ Long COvIO patients: © Curative therapeutic options available Oncology Annual US incidence: 1.9M Gn a M
Slide 18: Product Development Prioritization: Prevalence, Unmet Need & Access Landscape
Product Development Prioritization: Prevalence, Unmet Need & Access Landscape There had been an estimated In addition, ene an estimated 103 million 15.1% of all cumulative confirmed U.S. adults COVID-19 cases have experienced Long COVID as of May 8, 2023? Large numbers of Americans remain highly vul
Slide 19: TVGN 489: The First Clinical Product of ExacTcell
TVGN 489: The First Clinical Product of ExacTcell Designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. Antigen-presenting cell Antigen HLA Class-1 TR Infected
Slide 20: TVGN Was Designed to Overcome Expected Mutational Challenges
2 TVGN 489 Was Designed to Overcome Expected Mutational Challenges Most monoclonal antibodies lasted only months prior to market withdrawal and vaccines are requiring yearly revisions, but almost three years into development, TVGN 489’s COVID-19 peptide targets remain well preserved despite the cont
Slide 21: TVGN Was Designed to Overcome the Mutational Challenges of COVID-19
TVGN 489 Was Designed to Overcome the Mutational Challenges of COVID-19 Each dose level concluded with three patients rather than six and the treatment arm concluded with a total of 12 patients rather than 24, primarily due to the absence of appreciable toxicities across all dose levels. The compara
Slide 22: Proof of Concept Clinical Trial — Interventional Arm Patient Profiles
TVGN 489 Proof of Concept Clinical Trial — Interventional Arm Patient Profiles Patient Comorbidities Dosing Level 1 (1 x 10° cells/ke) Vaccination Status Variant African Amer Male Caucasian Female Hispanic Female Dosing Level 2 (3 x 10° cells/ke) Caucasian Male Hispanic Female Caucasian Female Dosin
Slide 23: Dose-Limiting Toxicity Criteria Trial Result
Dose-Limiting Toxicity Criteria Trial Result Interventional Versus Observational > Grade 3 acute infusion reaction None : * Cytokine release syndrome None 2 (Hypoxia and/or Hypotension) 3 Neurotoxicity None 2 3 2. Graft versus Host Disease None & Grade 4 or higher adverse events None = _=_ a - Inter
Slide 24: Rapid Viral Load Reduction After TVGN 489 Treatment
Positive Proof-of-Concept Clinical Trial - Rapid Viral Load Reduction After TVGN 489 Treatment COVID-19 viral presence was assessed by PCR in Thomas Jefferson University’s Clinical Pathology Laboratory. Baseline assessment revealed a substantial COVID- 19 burden in at least 10 of the 12 patients. De
Slide 25: Positive Proof-of-Concept Clinical Trial - Key Observations
Fo Product-Only Clone Sum Frequency Positive Proof-of-Concept Clinical Trial - Key Observations TVGN 489 COVID-19 reactive CD8+ T cells in treatment arm patients detected throughout the six month follow up. 2x10 1.5% 10" 1610 5x 10% Dose © one A Three = Four Subject © 014 © 164 © 174 > 25-1 © 20-1 “
Slide 26: Long COVID: Eradication and Restoration
Long COVID: Eradication and Restoration Recent studies! show that some Long COVID patients have lingering viral proteins, suggesting a persistent viral reservoir. This finding indicates that TVGN 489 CTLs could potentially be used to eliminate this reservoir and restore homeostasis. CHESS ATO Body H
Slide 27: ExacTcell in Oncology
ExacTcell in Oncology Lacking PD-1, our product should still function, even if oncology target cells express PD-L1. PD-L1 binds to PD-1 and inhibits T cell killing of tumor cell Tumor cell T call Blocking PD-Li or PD-1 allows T cell killing of tumor cell Tumor cell death T cell Blocking PD-L1 or PD-
Slide 28: ExacTcell in Oncology
ExacTcell in Oncology Unlike CAR-T or Bispecific T-cell Engager (BITE) antibody approaches, which recruit a heterogeneous group of T cells to the tumor, our approach would instead focus a highly purified population of CTLs on the tumor, which we believe may provide more potential to accomplish the t
Slide 29: Robust Research Pipeline
The candi TVGN 489 TVGN 601 TVGN 930 TVGN 920 TVGN 960 Acute covio-19* Long covio? Multiple sclerosis EBV-associated lymphomas Cervical cancer Mouth and throat Robust Research Pipeline We are committed to developing lifesaving therapies for viral diseases and cancers with high unmet need. Target Pop
Slide 30: Addressing the Needs of Large Patient Populations
Addressing the Needs of Large Patient Populations N 601 — Multiple Sclerosis Nearly one million people in the United States are living with MS* 2.8 million people are estimated to live with MS worldwide TWGN 930 — EBV-Associated Lymphomas EBV-related cancers have an incidence rate of 6.68 per 100,00
Slide 31: Pathway to Revenue
Pathway to Revenue Reflects management's current assumptions, estimates, projections and beliefs March 2021, April 2021 May 2021 Oct 2021 | | June 2020 iS ) a ) | Tevogen IN Founded Tv6N 489 TVG6N 489 VGN 489 ambulatory TVGN 489 fst pre-clinical first clinical acute-isk COVID-19, patient treated com
Slide 32: Tevogen.ai
TEVOGEN S ~ | Welcome to the forefront of NY ' innovation in the biotech industry, INS where human expertise and artificial UUTTUULLUUTUOT LETT intelligence merge to redefine the limits of scientific exploration Afordabilty and access for all are at the heart of Tevogen’s vision. In pursuit of that
Slide 33: Tevogen.ai Aims to Enhance Patient Access Utilizing AI Tools
Tevogen.ai Aims to Enhance Patient Access by Utilizing Artificial Intelligence-powered Tools Novel drug discovery | Enhance precision and success rates | Decrease costs and development time ‘Target Detection: We are exploring ways to deploy Al-powered Loss of exclusivity Loss of exclusivity, target
Slide 34: Healthcare Reimagined: Vision 2025
Healthcare Reimagined: Vision 2025 Where Efficiency Meets Equality with Integrated Solutions Healthcare is one $4.3 trillion of the largest U.S. health care spending sectors of the US economy Tevogen Holdings Vision 2025 Tevogen Tevogen Tevogen Tevogen Tevogen.ai Biotech Provider Pharmacy Health 14
Slide 35: In the Days Ahead — Novel Product Development at a Rapid Rate
In the Days Ahead — Novel Product Development at a Rapid Rate Advancing the clinical development of TVGN 489 for the treatment of COVID-19 and Long COVID + Launch a pivotal trial in COVID-19 patients with B cell malignancies in early 2024. + Launch clinical trials in Long COVID in approximately the
Slide 36: One Vision, One Community, a Healthier Tomorrow
One Vision, One Community, a Healthier Tomorrow
Slide 37: TeVOGE
TeVOGE UDN 05.2, Batch 1, Bag #250-42 HLA.A%02:01 Cytotoxic T-cell Lymphocytes Volume Frozen (mL): SomL. Celi Concentration: 26/ml. Date of Cryopreservation: 04/24/2021 Expiration: 04/24/2023 This product must be maintained at -150C or colder at all times until administered CAUTION: New Drug-Limited
Semper Paratus Acquisition — SPAC Merger (November 2023) on 6ix